Comparing Etoposide Phosphate and Etoposide in Cancer Treatment
Author Information
Author(s): RS de Jong, NH Mulder, DRA Uges, S Kau, B Winograd, DTh Sleijfer, HJM Groen, PHB Willemsel, WTA van der Graaf, EGE de Vries
Primary Institution: University Hospital Groningen
Hypothesis
Does etoposide phosphate provide better pharmacokinetics than oral etoposide?
Conclusion
Oral etoposide phosphate does not offer a clinically relevant benefit over oral etoposide.
Supporting Evidence
- The median AUCinf of etoposide was 77.7 mg 1-1 h after etoposide phosphate.
- Etoposide phosphate was undetectable in plasma after oral administration.
- Patients received a total of 59 treatment courses.
- Grade III or IV leucopenia developed in three patients (18%).
- Pharmacokinetic variability was high for both drugs.
Takeaway
This study looked at two types of cancer medicine, and found that one didn't work any better than the other.
Methodology
Patients were randomized to receive either etoposide phosphate or etoposide, with pharmacokinetic sampling conducted.
Limitations
The study had a small sample size and did not directly compare toxicities of both drugs.
Participant Demographics
Patients aged 18-75 with solid tumors, 12 males and 5 females.
Statistical Information
P-Value
0.05
Confidence Interval
95% Cl 61.3-100.5
Statistical Significance
p=0.05
Want to read the original?
Access the complete publication on the publisher's website